Zynerba Pharmaceuticals Shares Outstanding 2014-2019 | ZYNE

Zynerba Pharmaceuticals shares outstanding from 2014 to 2019. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
Zynerba Pharmaceuticals Annual Shares Outstanding
(Millions of Shares)
2018 15
2017 13
2016 9
2015 4
2014 1
2013 0
Zynerba Pharmaceuticals Quarterly Shares Outstanding
(Millions of Shares)
Q3 2019 23
Q2 2019 22
Q1 2019 19
Q4 2018 15
Q3 2018 17
Q2 2018 14
Q1 2018 13
Q4 2017 13
Q3 2017 13
Q2 2017 13
Q1 2017 12
Q4 2016 9
Q3 2016 9
Q2 2016 9
Q1 2016 9
Q4 2015 4
Q3 2015 6
Q2 2015 1
Q1 2015 1
Q4 2014 1
Q3 2014 1
Q2 2014 1
Q1 2014 0
Q4 2013
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.130B $0.000B
Zynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company which focuses on developing and commercializing proprietary synthetic cannabinoid therapeutics formulated for transdermal delivery. Its product candidates which are in clinical trial stage include ZYN002 and ZYN001 synthetic transdermal cannabinoid therapeutics for indications including refractory epilepsy, Fragile X syndrome, osteoarthritis, fibromyalgia and peripheral neuropathic pain. Zynerba Pharmaceuticals, Inc. is headquartered in Devon, Pennsylvania.
Stock Name Country Market Cap PE Ratio
Allergan (AGN) Ireland $61.270B 11.17
Teva Pharmaceutical Industries (TEVA) Israel $10.440B 4.25
Bausch Health Cos (BHC) Canada $10.337B 6.82
Mylan (MYL) United States $9.708B 4.35
Dr Reddy's Laboratories (RDY) India $6.778B 17.78
ASPEN PHARMACR (APNHY) South Africa $3.364B 0.00
Supernus Pharmaceuticals (SUPN) United States $1.145B 11.08
Amphastar Pharmaceuticals (AMPH) United States $0.910B 47.27
Homology Medicines (FIXX) United States $0.877B 0.00
Voyager Therapeutics (VYGR) United States $0.499B 0.00
Assembly Biosciences (ASMB) United States $0.461B 0.00
Akorn (AKRX) United States $0.459B 0.00
Progenics Pharmaceuticals (PGNX) United States $0.436B 0.00
Mallinckrodt Public Limited Company (MNK) United Kingdom $0.283B 0.39
Adamas Pharmaceuticals (ADMS) United States $0.174B 0.00
Sol-Gel Technologies (SLGL) Israel $0.163B 0.00
CymaBay Therapeutics (CBAY) United States $0.117B 0.00
Teligent (TLGT) United States $0.028B 0.00
China Pharma Holdings (CPHI) China $0.010B 0.00